EORTC-1709-BTG_CCTG-CE.8: A Study to Compare Marizomib in Combination with Standard Radiochemotherapy vs. Radiochemotherapy Alone in Patients with Newly- diagnosed Glioblastoma MIRAGE

Overview

About this study

The purpose of this study is to evaluate the safety and tolerability of marizomib in combination with Temozolomide-based radiochemotherapy versus standard Temozolomide-based radiochemotherapy alone in newly diagnosed glioblastoma patients. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Histologically confirmed newly diagnosed glioblastoma (WHO grade IV).
  • Tumor resection (gross total or partial), or open biopsy only (stereotactic biopsy not allowed)
  • Availability of FFPE tumor block or 24 unstained slides for MGMT analysis.
  • Patient must be eligible for standard TMZ/RT + TMZ.
  • Karnofsky performance score (KPS) ≥ 70.
  • Recovered from effects of surgery, postoperative infection and other complications of surgery (if any).
  • The patient is at least 18 years of age on day of signing informed consent.
  • Stable or decreasing dose of steroids for at least 1 week prior to inclusion.
  • The patient has a life expectancy of at least 3 months.
  • Patient has undergone a brain MRI within 14 days of randomization but after intervention (resection or biopsy).
  • The patient shows adequate organ functions as assessed by the specified laboratory values within 2 weeks prior to randomization defined as adequate bone marrow, renal and hepatic function within the following ranges:
    • WBC ≥ 3×10^9/L; 
    • ANC ≥ 1.5×10^9/L; 
    • Platelet count of ≥ 100×10^9/L independent of transfusion;
    • Hemoglobin ≥ 10 g/dl;
    • Total Bilirubin ≤ 1.5 ULN; 
    • ALT, AST, alkaline phosphatase (ALP) ≤ 2.5 × ULN;
    • Serum creatinine < 1.5 x ULN or creatinine clearance (CrCl) > 30 mL/min(using the Cockcroft-Gault formula).
  • Women of child bearing potential (WOCBP) must have a negative urine or serum pregnancy test within 7 days prior to randomization.
  • Patients of childbearing / reproductive potential must agree to use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 6 months after the last study treatment. A highly effective method of birth control is defined as those which result in low failure rate (i.e., less than 1 percent per year) when used consistently and correctly. Patients must also agree not to donate sperm during the study and for 6 months after receiving the last dose of study treatment. 
  • Women who are breast feeding must agree to discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment. 
  • Ability to take oral medication.
  • Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.
  • Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.

Exclusion Criteria:

  • Patients with known IDH mutation. IDH mutation testing should be onducted for younger patients( < 55 years old), patients with tumors with atypical features, or with history or present concurrent lower grade gliomas.
  • Prior treatment for glioblastoma other than surgery; prior RT to brain and/or prior chemotherapy for lower grade glioma. Placement of BCNU wafer during surgery is not allowed.
  • Planned additional treatment with Tumor-Treating Fields.
  • Known hypersensitivity to the active substance or any of the excipients in the IV formulation.
  • History of thrombotic or hemorrhagic stroke or myocardial infarction in past 6 months.
  • Congestive heart failure (New York Heart Association Class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, and myocardial infarction within 6 months prior to first dose.
  • Concurrent severe or uncontrolled medical disease (e.g., active systemic infection, diabetes, hypertension, coronary artery disease, psychiatric disorder) that, in the opinion of the investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study.
  • Known history or current evidence of active Hepatitis B (e.g., positive HBV surface antigen) or C (e.g., HCV RNA [qualitative] is detected) Known or current evidence of Human Immunodeficiency.
  • Virus (HIV) (positive HIV-1/2 antibodies) Prior or second invasive malignancy, except nonmelanoma skin cancer, completely resected cervical carcinoma in situ, low risk prostate cancer (cT1-2a N0 and Gleason score ≤ 6 and PSA < 10 ng/mL), either totally resected or irradiated with curative intent (with PSA of less than or equal to 0.1 ng/mL) or under active surveillance as per ESMO guidelines. Other cancers for which the subject has completed potentially curative treatment more than 3 years prior to study entry are allowed.
  • Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
    • Important note: All eligibility criteria must be adhered to, in case of deviation discussion with Headquarters and study coordinator is mandatory.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Maciej Mrugala, M.D., Ph.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Kurt Jaeckle, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Rochester, Minn.

Mayo Clinic principal investigator

Evanthia Galanis, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20473849

Mayo Clinic Footer